In a breakthrough that could reshape the landscape of metabolic medicine, researchers at Stanford Medicine have identified a naturally occurring molecule that mimics the appetite-suppressing effects of blockbuster weight-loss drugs like Ozempic (semaglutide) while potentially bypassing their most common and debilitating side effects.
The molecule, a 12-amino acid peptide dubbed BRP (BRINP2-related peptide), appears to influence weight loss through a highly localized pathway in the brain. Unlike current injectable therapies that act on receptors throughout the body, BRP’s localized activity in the hypothalamus suggests a “precision” approach to metabolic regulation. Published March 5 in the journal Nature, this discovery marks a significant leap forward in understanding the complex biochemical signals that govern human hunger.
The Chronology of a Digital Discovery
The identification of BRP was not a traditional "test-tube" discovery; it was the result of a sophisticated marriage between computational power and biological inquiry.
The Algorithmic Search
For decades, researchers have understood that prohormones—inactive precursor proteins—are the biological "raw material" for hormones. These proteins are sliced by enzymes into smaller, active fragments known as peptides. However, the sheer volume of possible fragments makes finding the ones that regulate metabolism akin to finding a needle in a haystack.
To accelerate this, the Stanford team, led by senior author Dr. Katrin Svensson and lead author Dr. Laetitia Coassolo, developed a proprietary computer algorithm titled "Peptide Predictor."
- Filtering the Proteome: The team scanned all 20,000 human protein-coding genes, filtering for proteins secreted outside the cell—a hallmark of signaling hormones.
- Mapping Cleavage Sites: The algorithm searched for specific sequences where the enzyme prohormone convertase 1/3 (PC1/3)—a known regulator of metabolism—typically cuts proteins.
- Refining the Candidates: This narrowed the field from the entire human proteome to 373 prohormones, which the model estimated could yield 2,683 distinct peptides.
- Targeted Testing: Researchers selected 100 high-probability candidates and tested them on neuronal cell cultures.
The “Outsized” Result
The experiment yielded a surprising candidate. While GLP-1—the foundation of current weight-loss medications—increased neuronal activity by three times in laboratory tests, the tiny 12-amino acid peptide BRP triggered a tenfold increase in activity. This profound reaction suggested that BRP was not merely a peripheral signal, but a potent, highly specific activator of the neural pathways responsible for energy balance.
Supporting Data: From Cellular Models to Metabolic Impact
Following the success of the cell-based assays, the researchers transitioned to animal models to observe how BRP functioned in a living, breathing system. The results, particularly regarding efficacy and side-effect profiles, were stark.
Dramatic Reductions in Intake
In studies involving both lean mice and minipigs—the latter being a preferred model due to their metabolic similarities to humans—intramuscular injections of BRP prior to feeding resulted in a 50% reduction in food intake within an hour.
Fat Loss vs. Muscle Preservation
Perhaps the most compelling data emerged from a 14-day study on obese mice. The subjects treated with daily BRP injections lost an average of 3 grams of body mass. Critically, the researchers noted that nearly the entirety of this loss was attributed to body fat. In contrast, the control group, which did not receive the peptide, gained 3 grams of weight over the same period. Furthermore, the treated mice exhibited enhanced insulin sensitivity and improved glucose tolerance, addressing two of the primary markers of metabolic syndrome.
The Side-Effect Profile
Current GLP-1 receptor agonists (GLP-1RAs) are highly effective, but their systemic distribution often leads to gastrointestinal distress, including nausea and severe constipation. Because these drugs target receptors in the gut and pancreas, they slow digestive transit.
BRP, conversely, appeared to act exclusively in the hypothalamus. In behavioral testing, researchers found:
- No change in fecal production: Indicating that BRP does not slow the digestive tract.
- No behavioral changes: No increased anxiety or changes in movement were observed.
- Preservation of muscle: Unlike some therapies that cause systemic muscle wasting due to rapid, non-selective weight loss, BRP-treated subjects retained their muscle mass.
Official Responses and Expert Perspective
Dr. Katrin Svensson, assistant professor of pathology at Stanford Medicine, emphasizes that the specificity of BRP is the key to its potential. "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues," she noted. "That’s why Ozempic has widespread effects. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
While the scientific community has reacted with cautious optimism, the research team is already moving to the next stage of development. Dr. Svensson has co-founded a biotechnology venture, Merrifield Therapeutics, with the specific intent of moving BRP into human clinical trials.
The researchers acknowledged that the study is currently limited to animal models. "The lack of effective drugs to treat obesity in humans has been a problem for decades," Svensson said. "Nothing we’ve tested before has compared to semaglutide’s ability to decrease appetite and body weight. We are very eager to learn if it is safe and effective in humans."
Implications for Future Obesity Treatment
The discovery of BRP arrives at a pivotal moment in global health. As obesity rates continue to climb, the current gold standard of GLP-1 therapies is facing supply chain shortages, high costs, and patient attrition due to side effects.
A New Class of Therapeutics?
The "precision" nature of BRP suggests that it may represent an entirely new class of anti-obesity medications. If BRP can replicate its animal-model success in human clinical trials, it could serve as a highly tolerable option for patients who cannot tolerate the gastrointestinal side effects of current medications.
Addressing the “Persistence” Challenge
The path to clinical application remains complex. Small peptides are inherently unstable and are often broken down by the body’s enzymes within minutes. For BRP to become a viable therapeutic, the research team must overcome the hurdle of durability. Ongoing studies are focused on "peptide engineering"—modifying the molecule to extend its half-life in the bloodstream, which would allow for a more practical, less frequent dosing schedule for patients.
Next Steps: The Hunt for the Receptor
A critical piece of the puzzle remains missing: the specific cell-surface receptor that BRP binds to. Identifying this receptor is the team’s current priority, as it will allow researchers to map the precise signaling cascade triggered by the peptide. Understanding this mechanism is vital not only for safety but for identifying potential biomarkers that could predict which patients will respond best to the treatment.
The collaboration, which included researchers from the University of California, Berkeley, the University of Minnesota, and the University of British Columbia, highlights the massive, interdisciplinary effort required to solve the riddle of metabolic regulation. Funded by a wide range of institutions, including the National Institutes of Health and the Stanford SPARK Translational Research Program, the project stands as a testament to the power of integrating AI-driven discovery with rigorous biological verification.
As the scientific community awaits the results of future human trials, the discovery of BRP offers a glimmer of hope: that the next generation of weight-loss drugs may be not only more effective but also more refined, working in harmony with the body’s natural chemistry rather than overwhelming it.
